Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

Veritas’ myBRCA breast and ovarian cancer genetic screening test receives CE mark approval

US-based Veritas Genetics has obtained CE mark approval for its hereditary breast and ovarian cancer genetic screening test, myBRCA.

Using proprietary gene-targeting technology, myBRCA sequences BRCA1 and BRCA2 genes. It was introduced in North America in May this year.

Veritas Genetics CEO Mirza Cifric said: "Working closely with European oncology researchers, we validated myBRCA across ethnicities, making this a very comprehensive test especially for European population.

"With the CE mark approval, we can now offer myBRCA across Europe, starting with a select group of 15 countries."

Performed in a clinical lab, the saliva-based test is said to identify mutations in BRCA1 and BRCA2. It uses a database representing over half a million patients and 8,000 known mutations.

According to the firm, breast and ovarian cancer risk is high in individuals with a known family history of these cancers and around 50% of women with BRCA1 and BRCA2 mutations have no substantial family history of breast and ovarian cancer.

Veritas Genetics founder and chief scientific officer Preston Estep III said: "We are dedicated to making genetic information accessible globally so everyone can make informed decisions about disease prevention and early detection."